Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for...

Related Keywords

,Robert Weinstein ,Exchange Commission ,Drug Administration ,Prnewswire Synaptogenix Inc ,Nasdaq ,Synaptogenix Inc ,Advanced Alzheimer ,About Synaptogenix ,Health Supported Phase ,Orphan Drug Designation ,Media Contact ,Synaptogenix ,Nc ,